Abstract
Diabetes mellitus is the prominent metabolic disorder affecting 422 million people around the globe and cause severe associated problems like kidney disorders, heart and nervous system diseases, leg amputation and retinopathy. Currently marketed antidiabetic drugs are failing in containment of this disorder that arise a need for novel and potent antidiabetic agents. α-Glucosidase provide a viable target to tackle this disorder and attracted significant attention of medicinal chemists globally. Recent literature reports revealed improved therapeutic potential of α-glucosidase inhibitors due to their synergistic potency, better safety and competitive type of inhibition. Medicinal chemists have gone to great extents for the design of novel α-glucosidase inhibitors by generating structural hybrids of different key molecules, heterocycles with improved binding affinities and potency towards the enzyme. This article summarized recently published α-glucosidase inhibitors as potential antidiabetic agents. Their pharmacological outputs, structural-activity relationships, mechanistic and in silico studies are well analyzed. This article will be highly useful for the researchers working in this filed to design and develop novel and potent α-glucosidase inhibitors as potential antidiabetic agents with improve potency and therapeutic efficacy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.